Table 2.
Vaccine efficacy against HPV-16/18-associated CIN3+ in the analytic cohort
| Year | Study Arm | Number of women included | Women with CIN3+ | Rate per 100 women (95% CI) | Cumulative Rate per 100 women (95% CI) | Vaccine Efficacy (95% CI) | Cumulative Vaccine Efficacy (95% CI) |
|---|---|---|---|---|---|---|---|
| 0 | HPV | 2635 | 0 | 0·00 (0·00 – 0·11) | 0·00 (0·00 – 0·11) | - | - |
| Control | 2677 | 0 | 0·00 (0·00 – 0·11) | 0·00 (0·00 – 0·11) | |||
| 1 | HPV | 2551 | 1 | 0·04 (0·00 – 0·19) | 0·04 (0·00 – 0·19) | -Infinity | -Infinity |
| Control | 2586 | 0 | 0·00 (0·00 – 0·12) | 0·00 (0·00 – 0·12) | |||
| 2 | HPV | 2488 | 0 | 0·00 (0·00 – 0·12) | 0·04 (0·00 – 0·20) | - | -Infinity |
| Control | 2549 | 0 | 0·00 (0·00 – 0·12) | 0·00 (0·00 – 0·12) | |||
| 3 | HPV | 2429 | 0 | 0·00 (0·00 – 0·12) | 0·04 (0·00 – 0·20) | - | -Infinity |
| Control | 2480 | 0 | 0·00 (0·00 – 0·12) | 0·00 (0·00 – 0·12) | |||
| 4 | HPV | 2477 | 1 | 0·04 (0·00 – 0·20) | 0·08 (0·01 – 0·26) | 83·0 (−15·4 – 99·3) | 66·4 (−175·4 – 97·3) |
| Control | 2532 | 6 | 0·24 (0·10 – 0·49) | 0·24 (0·10 – 0·49) | |||
| 7 | HPV | 1950 | 0 | 0·00 (0·00 – 0·15) | 0·08 (0·01 – 0·28) | 100 (−40·1 – 100·0) | 80·1 (−39·5 – 98·1) |
| UCG | 2451 | 4 | 0·16 (0·05 – 0·39) | 0·40 (0·20 – 0·71) | |||
| 9 | HPV | 1815 | 0 | 0·00 (0·00 – 0·16) | 0·08 (0·01 – 0·29) | 100 (44·0 – 100·0) | 89·5 (37·0 – 98·9) |
| UCG | 2238 | 8 | 0·36 (0·17 – 0·68) | 0·76 (0·46 – 1·17) | |||
| 11 | HPV | 1913 | 0 | 0·00 (0·00 – 0·16) | 0·08 (0·01 – 0·29) | 100 (78·8 – 100·0) | 94·9 (73·7 – 99·4) |
| UCG | 2237 | 18 | 0·80 (0·49 – 1·24) | 1·56 (1·11 – 2·13) | |||
| Total | 38 |